{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".396","upperLimit":".722","value":".564"},{"groupId":"OG001","lowerLimit":".569","upperLimit":".866","value":".737"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Disease response status is based on the IMWG criteria being held for two consecutive evaluations at least 4 weeks apart. Clinical benefit rate (CBR) is defined as proportion of patients with minimal response (MR) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Phase II Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}